Heidi Roggie
Nurse Practitioner · Lowville, NYNPI 1326685199
Payments from drug & device makers
Across 200 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$561
- AbbVie$497
- Lilly USA, LLC$369
- AstraZeneca$303
- Amgen$233
- Abbott$199
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,396100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $561 |
| AbbVie | 32 | $497 |
| Lilly USA, LLC | 25 | $369 |
| AstraZeneca | 19 | $303 |
| Amgen | 15 | $233 |
| Abbott | 10 | $199 |
| Exact Sciences | 8 | $168 |
| Merck | 8 | $148 |
| GSK | 9 | $137 |
| Dexcom, Inc. | 5 | $128 |
| Otsuka America Pharmaceutical, Inc. | 5 | $122 |
| Pfizer | 6 | $111 |
| Astellas Pharma US Inc | 5 | $86 |
| Phathom Pharmaceuticals, Inc. | 3 | $66 |
| Novartis | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Organon | 1 | $26 |
| Boehringer Ingelheim | 2 | $26 |
| Lundbeck LLC | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,396 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $40,147 |
| JardianceEmpagliflozin | 21 | $35,776 |
| TrulicityDulaglutide | 21 | $32,668 |
| EliquisApixaban | 35 | $32,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $29,193 |
| FarxigaDapagliflozin Propanediol | 17 | $27,560 |
| ProliaDenosumab | 13 | $22,739 |
| LinzessLinaclotide | 12 | $10,125 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,793 |
| Icosapent Ethyl | 12 | $2,677 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,736 |
| Duloxetine Hcl | 26 | $1,432 |
| Levothyroxine Sodium | 134 | $1,386 |
| Gabapentin | 48 | $1,216 |
| Ultra-Fine Micro Pen NeedlePen Needle, Diabetic | 11 | $1,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $561 | $40,14727 claims |
| Boehringer IngelheimJardiance | $26 | $35,77621 claims |
| Lilly USA, LLCTrulicity | $369 | $32,66821 claims |
| PfizerEliquis | $111 | $32,56335 claims |
| GSKTrelegy Ellipta | $137 | $29,19324 claims |
| AstraZenecaFarxiga | $303 | $27,56017 claims |
| AmgenProlia | $233 | $22,73913 claims |
| AbbVieLinzess | $497 | $10,12512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Lowville
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.